Inactive Instrument

US Rare Earth Minerals Inc Stock Other OTC

US9034101082

Biotechnology & Medical Research

End-of-day quote Other OTC Other stock markets
- ^USD	-

05-15	Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-15	Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

on all subscriptions*

Last days

Enjoy this offer

* See conditions under "Our services"

Valuation: US Rare Earth Minerals Inc

Market Cap	3.46M 2.99M 2.75M 2.58M 4.83M 331M 4.91M 32.62M 12.68M 160M 12.99M 12.71M 554M	P/E Ratio 2024	-5.27x	P/E Ratio 2025	-3.28x
Enterprise Value	4.2M 3.63M 3.34M 3.13M 5.87M 402M 5.96M 39.61M 15.39M 194M 15.77M 15.43M 672M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	99.38%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Latest news : US Rare Earth Minerals Inc

05-15	Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-15	Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-14	Bioxytran, Inc. Auditor Raises 'Going Concern' Doubt	CI
03-17	Bioxytran, Inc. announced that it has received $1.158942 million in funding	CI
03-04	Bioxytran Inc Announces Positive Dose Optimization Results And Advances Toward Phase 3 Registrational Trial For ProLectin-M	CI
03-02	Bioxytran Inc reports positive phase 1b/2a clinical study results for Prolectin-M, broad-range antiviral drug in mild to moderate Covid-19	RE
02-17	Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical Ltd for A-SUQAR Dietary Supplement	CI
02-11	Bioxytran reports positive phase 2 results demonstrating rapid viral clearance with Prolectin-Mbioxytran	RE
02-11	Bioxytran, Inc. Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with Prolectin-Mbioxytran	CI
02-02	Bioxytran, Inc. and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics	CI
12-15	Bioxytran, Inc. Announces Resignation of Anders Utter from Board of Directors and Chair of Audit Committee	CI
11-14	Bioxytran, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-13	Bioxytran, Inc. announced that it has received $0.43 million in funding	CI

More news

Press Releases: US Rare Earth Minerals Inc

05-29	Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25	AQ
03-20	BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT	AQ
03-04	Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M	AQ
02-23	Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus	AQ
02-17	Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement	AQ

More press releases

Managers and Directors: US Rare Earth Minerals Inc

Manager	Title	Age	Since
David Platt CEO	Chief Executive Officer	73	2018-08-31
Ola Soderquist DFI	Director of Finance/CFO	65	2018-08-31
Leslie Ajayi CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Dale Conaway BRD	Director/Board Member	71	2018-11-01
Alan Hoberman BRD	Director/Board Member	73	2018-11-01
David Platt CHM	Chairman	73	2018-08-31

More insiders

Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with intended applications, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

Employees

Sector

Biotechnology & Medical Research

More about the company

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrows Top Investments!

SEIZE THE OFFER!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGENX SE	+1.65%	+11.53%	+52.68%	+112.78%	54.82B
WUXI APPTEC CO., LTD.	+0.03%	-1.80%	+49.57%	+43.94%	43.27B
BIONTECH SE	+3.93%	+1.23%	-16.23%	-18.04%	21.79B
INSMED INCORPORATED	+5.27%	-6.87%	+6.37%	+388.48%	19.92B
WUXI BIOLOGICS (CAYMAN) INC.	+0.81%	-8.38%	+12.77%	-33.24%	15.67B
GENMAB A/S	+0.53%	+6.07%	+8.13%	-39.59%	15.26B
EXELIXIS, INC.	+1.75%	+3.68%	+25.82%	+178.65%	13.22B
PHARMAESSENTIA CORPORATION	-5.27%	+3.89%	+90.88%	+208.02%	11.58B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.74%	-1.05%	+12.88%	-	11.94B
Average	+0.27%	-0.58%	+26.98%	+105.12%	23.05B
Weighted average by Cap.	+0.70%	+1.16%	+32.19%	+97.55%

	2024	2025
Net sales	-	-
Net income	-2.37M -2.04M -1.88M -1.76M -3.31M -227M -3.36M -22.31M -8.67M -109M -8.88M -8.69M -379M	-2.12M -1.83M -1.69M -1.58M -2.97M -203M -3.01M -20.02M -7.78M -98.12M -7.97M -7.8M -340M
Net Debt	1.09M 941K 866K 812K 1.52M 104M 1.55M 10.27M 3.99M 50.32M 4.09M 4M 174M	741K 640K 589K 552K 1.03M 70.93M 1.05M 6.98M 2.71M 34.23M 2.78M 2.72M 119M

US Rare Earth Minerals Inc Stock Other OTC

Stocks

US9034101082

Biotechnology & Medical Research

Valuation: US Rare Earth Minerals Inc

Latest news : US Rare Earth Minerals Inc

Press Releases: US Rare Earth Minerals Inc

Managers and Directors: US Rare Earth Minerals Inc

Bio Therapeutic Drugs

Financials

Company Profile